For the quarter ended September 2025, Moderna (MRNA) reported revenue of $1.02 billion, down 45.4% over the same period last year. EPS came in at -$0.51, compared to $0.03 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $860.07 million, representing a surprise of +18.13%. The company delivered an EPS surprise of +76.28%, with the consensus EPS estimate being -$2.15.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Moderna performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Product sales- Rest of world: $175 million versus $196.36 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -46% change.
- Product sales- United States: $782 million compared to the $499.39 million average estimate based on two analysts. The reported number represents a change of -35.6% year over year.
- Revenue- Net Product sales: $973 million versus $835.12 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -46.5% change.
- Revenue- Other revenue: $43 million compared to the $25.19 million average estimate based on six analysts. The reported number represents a change of +2.4% year over year.
- Revenue- Other revenue- Grant revenue: $14 million versus $5.56 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +100% change.
View all Key Company Metrics for Moderna here>>>
Shares of Moderna have returned -15.6% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Moderna, Inc. (MRNA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
